Short-term Clinical Efficacy And Safety Of Dapagliflozin In The Treatment Of Type 2 Diabetes

Objective: Different doses of dapagliflozin were given to patients with type 2 diabetes,and FPG,PBG,blood pressure,body weight,BMI,waist circumference,hypoglycemia events and other adverse events were compared before and after treatment to observe different doses of dapagliflozin 2 Short-term clinical efficacy and safety of type 2 diabetes.Methods: The patients with type 2 diabetes who did not meet the blood glucose levels who were admitted to the endocrinology clinic of the Affiliated Hospital of North Sichuan Medical College from November 2017 to October 2018 and who voluntarily entered the study were enrolled.All patients were diagnosed with diabetes according to the 1999 WHO standard.51 patients(3 patients with shedding)were included,and 48 patients were finally completed.They were divided into group A(24 patients)and group B(24 patients).Both groups were treated with dapagliflozin orally in the original hypoglycemic treatment regimen.Group: dapagliflozin 5 mg/d,group B: dapagliflozin 10 mg/d.Observe for 2 weeks.Exit the study if a serious adverse reaction occurs or the patient withdraws.FPG,PBG,blood pressure,body weight,BMI,waist circumference were measured before and after treatment.The incidence of hypoglycemia and other adverse events were recorded,and statistical analysis was performed using SPSS19.0 statistical software.The difference was statistically significant at p<0.05.significance.Results: In this study,48 patients with T2 DM were enrolled,including 34 males and 14 females,aged 51±12 years,with a course of 6(1-10)years,divided into groups A and B.1.There was no significant difference in age,gender,course of disease,HbA1 c,PBG,blood pressure,body weight,BMI and waist circumference between the two groups(p>0.05).The FPG of group B was higher than that of group A(p<0.05);2.After 2 weeks of treatment,the FPG,PBG,SBP,DBP,body weight and BMI of the two groups were significantly lower than those before treatment(p<0.05).There was no significant difference between the waist circumference and the pre-treatment(p<0.05);3.The median FPG difference before and after treatment in group B was greater than that in group A(p<0.05).The median difference of PBG and blood pressure before and after treatment in group B was slightly larger than that in group A.The difference was not statistically significant(p>0.05);There was no significant difference in the median weight-related index between group B and group A before and after treatment(p>0.05);4.Hypoglycemia event,2 cases in group A,1 case in group B,all grade 1 hypoglycemia;positive urinary ketone,1 case in group B;urinary tract infection,1 case in group B;the incidence of hypoglycemia,the incidence of urinary ketone,and the incidence of urinary tract infection between the two groups were not statistically significant(p>0.05).Conclusion:(1)Dapagliflozin can effectively reduce FPG and PBG in patients with T2 DM in a short period of time;(2)dapagliflozin can slightly reduce blood pressure and body weight in patients with T2 DM in a short period of time;(3)daily 5mg dapagliflozin shows hypoglycemic,hypotensive,and weight-reducing effects in the short term.;(4)the short-term hypoglycemic effect of 10 mg of dapagliflozin is better than 5 mg,but it does not show more advantages in reducing blood pressure and weight loss;(5)dapagliflozin is clinically safe,but has a risk of genitourinary infections and ketosis.